The 2009 A (H1N1) influenza virus pandemic: A review.
Identifieur interne : 001142 ( PubMed/Checkpoint ); précédent : 001141; suivant : 001143The 2009 A (H1N1) influenza virus pandemic: A review.
Auteurs : Marc P. Girard [France] ; John S. Tam ; Olga M. Assossou ; Marie Paule KienySource :
- Vaccine [ 1873-2518 ] ; 2010.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Antiviraux (pharmacologie), Coût de la maladie, Enfant, Enfant d'âge préscolaire, Facteurs de risque, Femelle, Flambées de maladies, Grippe humaine (), Grippe humaine (transmission), Grippe humaine (virologie), Grippe humaine (épidémiologie), Grossesse, Humains, Jeune adulte, Nourrisson, Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (immunologie), Suidae, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccins antigrippaux (immunologie).
- MESH :
- génétique : Sous-type H1N1 du virus de la grippe A.
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- pharmacologie : Antiviraux.
- virologie : Grippe humaine.
- épidémiologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Coût de la maladie, Enfant, Enfant d'âge préscolaire, Facteurs de risque, Femelle, Flambées de maladies, Grippe humaine, Grossesse, Humains, Jeune adulte, Nourrisson, Sous-type H1N1 du virus de la grippe A, Suidae, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Antiviral Agents (pharmacology), Child, Child, Preschool, Cost of Illness, Disease Outbreaks, Female, Humans, Infant, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (transmission), Influenza, Human (virology), Middle Aged, Pregnancy, Risk Factors, Swine, Young Adult.
- MESH :
- chemical , immunology : Influenza Vaccines.
- chemical , pharmacology : Antiviral Agents.
- drug effects : Influenza A Virus, H1N1 Subtype.
- epidemiology : Influenza, Human.
- genetics : Influenza A Virus, H1N1 Subtype.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human.
- transmission : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Child, Child, Preschool, Cost of Illness, Disease Outbreaks, Female, Humans, Infant, Middle Aged, Pregnancy, Risk Factors, Swine, Young Adult.
Abstract
In March and early April 2009 a new swine-origin influenza virus (S-OIV), A (H1N1), emerged in Mexico and the USA. The virus quickly spread worldwide through human-to-human transmission. In view of the number of countries and communities which were reporting human cases, the World Health Organization raised the influenza pandemic alert to the highest level (level 6) on June 11, 2009. The propensity of the virus to primarily affect children, young adults and pregnant women, especially those with an underlying lung or cardiac disease condition, and the substantial increase in rate of hospitalizations, prompted the efforts of the pharmaceutical industry, including new manufacturers from China, Thailand, India and South America, to develop pandemic H1N1 influenza vaccines. All currently registered vaccines were tested for safety and immunogenicity in clinical trials on human volunteers. All were found to be safe and to elicit potentially protective antibody responses after the administration of a single dose of vaccine, including split inactivated vaccines with or without adjuvant, whole-virion vaccines and live-attenuated vaccines. The need for an increased surveillance of influenza virus circulation in swine is outlined.
DOI: 10.1016/j.vaccine.2010.05.031
PubMed: 20553769
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20553769Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The 2009 A (H1N1) influenza virus pandemic: A review.</title><author><name sortKey="Girard, Marc P" sort="Girard, Marc P" uniqKey="Girard M" first="Marc P" last="Girard">Marc P. Girard</name><affiliation wicri:level="3"><nlm:affiliation>University Paris-7 Denis Diderot, 39 rue Seignemartin, 69008, Lyon, France. marc.girard36@wanadoo.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Paris-7 Denis Diderot, 39 rue Seignemartin, 69008, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S" last="Tam">John S. Tam</name></author><author><name sortKey="Assossou, Olga M" sort="Assossou, Olga M" uniqKey="Assossou O" first="Olga M" last="Assossou">Olga M. Assossou</name></author><author><name sortKey="Kieny, Marie Paule" sort="Kieny, Marie Paule" uniqKey="Kieny M" first="Marie Paule" last="Kieny">Marie Paule Kieny</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20553769</idno><idno type="pmid">20553769</idno><idno type="doi">10.1016/j.vaccine.2010.05.031</idno><idno type="wicri:Area/PubMed/Corpus">001314</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001314</idno><idno type="wicri:Area/PubMed/Curation">001314</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001314</idno><idno type="wicri:Area/PubMed/Checkpoint">001142</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001142</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The 2009 A (H1N1) influenza virus pandemic: A review.</title><author><name sortKey="Girard, Marc P" sort="Girard, Marc P" uniqKey="Girard M" first="Marc P" last="Girard">Marc P. Girard</name><affiliation wicri:level="3"><nlm:affiliation>University Paris-7 Denis Diderot, 39 rue Seignemartin, 69008, Lyon, France. marc.girard36@wanadoo.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Paris-7 Denis Diderot, 39 rue Seignemartin, 69008, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S" last="Tam">John S. Tam</name></author><author><name sortKey="Assossou, Olga M" sort="Assossou, Olga M" uniqKey="Assossou O" first="Olga M" last="Assossou">Olga M. Assossou</name></author><author><name sortKey="Kieny, Marie Paule" sort="Kieny, Marie Paule" uniqKey="Kieny M" first="Marie Paule" last="Kieny">Marie Paule Kieny</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Child</term><term>Child, Preschool</term><term>Cost of Illness</term><term>Disease Outbreaks</term><term>Female</term><term>Humans</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (genetics)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (transmission)</term><term>Influenza, Human (virology)</term><term>Middle Aged</term><term>Pregnancy</term><term>Risk Factors</term><term>Swine</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Coût de la maladie</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de risque</term><term>Femelle</term><term>Flambées de maladies</term><term>Grippe humaine ()</term><term>Grippe humaine (transmission)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Grossesse</term><term>Humains</term><term>Jeune adulte</term><term>Nourrisson</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sous-type H1N1 du virus de la grippe A (génétique)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Suidae</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Cost of Illness</term><term>Disease Outbreaks</term><term>Female</term><term>Humans</term><term>Infant</term><term>Middle Aged</term><term>Pregnancy</term><term>Risk Factors</term><term>Swine</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Coût de la maladie</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de risque</term><term>Femelle</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Grossesse</term><term>Humains</term><term>Jeune adulte</term><term>Nourrisson</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Suidae</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In March and early April 2009 a new swine-origin influenza virus (S-OIV), A (H1N1), emerged in Mexico and the USA. The virus quickly spread worldwide through human-to-human transmission. In view of the number of countries and communities which were reporting human cases, the World Health Organization raised the influenza pandemic alert to the highest level (level 6) on June 11, 2009. The propensity of the virus to primarily affect children, young adults and pregnant women, especially those with an underlying lung or cardiac disease condition, and the substantial increase in rate of hospitalizations, prompted the efforts of the pharmaceutical industry, including new manufacturers from China, Thailand, India and South America, to develop pandemic H1N1 influenza vaccines. All currently registered vaccines were tested for safety and immunogenicity in clinical trials on human volunteers. All were found to be safe and to elicit potentially protective antibody responses after the administration of a single dose of vaccine, including split inactivated vaccines with or without adjuvant, whole-virion vaccines and live-attenuated vaccines. The need for an increased surveillance of influenza virus circulation in swine is outlined.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20553769</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>31</Issue><PubDate><Year>2010</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>The 2009 A (H1N1) influenza virus pandemic: A review.</ArticleTitle><Pagination><MedlinePgn>4895-902</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2010.05.031</ELocationID><Abstract><AbstractText>In March and early April 2009 a new swine-origin influenza virus (S-OIV), A (H1N1), emerged in Mexico and the USA. The virus quickly spread worldwide through human-to-human transmission. In view of the number of countries and communities which were reporting human cases, the World Health Organization raised the influenza pandemic alert to the highest level (level 6) on June 11, 2009. The propensity of the virus to primarily affect children, young adults and pregnant women, especially those with an underlying lung or cardiac disease condition, and the substantial increase in rate of hospitalizations, prompted the efforts of the pharmaceutical industry, including new manufacturers from China, Thailand, India and South America, to develop pandemic H1N1 influenza vaccines. All currently registered vaccines were tested for safety and immunogenicity in clinical trials on human volunteers. All were found to be safe and to elicit potentially protective antibody responses after the administration of a single dose of vaccine, including split inactivated vaccines with or without adjuvant, whole-virion vaccines and live-attenuated vaccines. The need for an increased surveillance of influenza virus circulation in swine is outlined.</AbstractText><CopyrightInformation>Copyright 2010. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girard</LastName><ForeName>Marc P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>University Paris-7 Denis Diderot, 39 rue Seignemartin, 69008, Lyon, France. marc.girard36@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>John S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Assossou</LastName><ForeName>Olga M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Kieny</LastName><ForeName>Marie Paule</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>114</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>02</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20553769</ArticleId><ArticleId IdType="pii">S0264-410X(10)00719-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2010.05.031</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><noCountry><name sortKey="Assossou, Olga M" sort="Assossou, Olga M" uniqKey="Assossou O" first="Olga M" last="Assossou">Olga M. Assossou</name><name sortKey="Kieny, Marie Paule" sort="Kieny, Marie Paule" uniqKey="Kieny M" first="Marie Paule" last="Kieny">Marie Paule Kieny</name><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S" last="Tam">John S. Tam</name></noCountry><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Girard, Marc P" sort="Girard, Marc P" uniqKey="Girard M" first="Marc P" last="Girard">Marc P. Girard</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001142 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001142 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:20553769
|texte= The 2009 A (H1N1) influenza virus pandemic: A review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20553769" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |